Telix Pharmaceuticals Limited (TLX) Discusses Revenue Growth, Prostate Cancer Imaging Portfolio, and Expansion into Brain and Kidney Cancer Transcript

Not financial advice. The Big Market Report aggregates news for informational purposes only. Nothing on this site constitutes investment advice. Equities and other securities are subject to market risk. Always do your own research and consult a qualified financial advisor before making any investment decisions. Full disclaimer →